AndhraNews.net
Home » Business News » 2012 » April » April 24, 2012

RECORDATI Acquires Six OTC Products in Germany


April 24, 2012 - Milan, Italy

Recordati announces the acquisition of themarketingauthorizations, the trademarks and additional assets concerning sixOTCpharmaceuticals for Germany from Cilag GmbH International and McNeil GmbH& Co.oHG. The products acquired are JHP-Rödler® (mint oilindicated for digestivedisorder, headache, cough and cold), Betadorm® D (Diphenhydramine HClindicatedfor sleep disorders), Rhinopront® (pseudoephedrine+triprolidineindicated forrhinitis and head colds), Collomack® Topical (salicylic acidsolution, an anti-corn preparation), Tirgon® (bisacodyl for constipation) andXitix® (vitamin Clozenges to treat vitamin C deficiency). Estimated 2012 sales forthe sixproducts are of around EUR 6 million.

"The acquisition by our German subsidiary of these six well knownbrandsrepresents an interesting opportunity to strengthen RecordatiPharma's OTCproduct portfolio", declared Giovanni Recordati, Chairman and CEOof theRecordati Group. "The OTC pharmaceutical segment in Germany is worth aroundEUR 4billion and represents a share in units of 52% of the overallpharmaceuticalmarket. Together with the existing OTC portfolio, which includes wellknownbrands such as Mirfulan®, Osteoplus®, Dolobene®,Flosa® and Silibene®, theGerman subsidiary is now able to better exploit the OTC marketpotential bybuilding a dedicated sales organization".

Recordati, established in 1926, is a European pharmaceutical group,listed onthe Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM,ISIN IT0003828271), with a total staff of over 3,200, dedicated to theresearch,development, manufacturing and marketing of pharmaceuticals. It hasheadquartersin Milan, Italy, operations in the main European countries, and agrowingpresence in the new markets of Central and Eastern Europe. A Europeanfieldforce of around 1,700 medical representatives promotes a widerange ofinnovative pharmaceuticals, both proprietary and under license, in anumber oftherapeutic areas including a specialized business dedicated totreatments forrare diseases. Recordati's current and growing coverage of theEuropeanpharmaceutical market makes it a partner of choice for new product licensesfromcompanies which do not have European marketing organizations.Recordati iscommitted to the research and development of new drug entitieswithin thecardiovascular and urogenital therapeutic areas and of treatments forrarediseases. Consolidated revenue for 2011 was EUR 762.0 million, operatingincomewas EUR 163.5 million and net income was EUR 116.4 million.

Statements contained in this release, other than historical facts, are"forward-looking statements" (as such term is defined in the PrivateSecuritiesLitigation Reform Act of 1995). These statements are based oncurrentlyavailable information, on current best estimates, and on assumptionsbelieved tobe reasonable. This information, these estimates and assumptions may proveto beincomplete or erroneous, and involve numerous risks and uncertainties,beyondthe Company's control. Hence, actual results may differ materially fromthoseexpressed or implied by such forward-looking statements. Allmentions anddescriptions of Recordati products are intended solely as informationon thegeneral nature of the company's activities and are not intended toindicate theadvisability of administering any product in any particular instance.

Recordati acquires six OTC products in Germany:http://hugin.info/143644/R/1605393/508401.pdf

This announcement is distributed by Thomson Reuters on behalf ofThomson Reuters clients. The owner of this announcement warrants that:(i) the releases contained herein are protected by copyright and other applicable laws; and(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: RECORDATI via Thomson Reuters ONE[HUG#1605393]

For further information:

Recordati website: www.recordati.com

RECORDATI
Via M. Civitali, 1
MILANO (MI) 20148
Phone: 39 02 48787340

MarketWire

Comment on this story

Share